Elbe Launches Amatem Softgel In Style

– As Experts affirm bioavailability, patient compliance

Poised to reduce the prevalence of malaria in the country, Elbe Pharma Nigeria Limited, on 18 July 2018, officially unveiled Amatem Forte Softgel – which has been described as an innovative antimalarial, with benefits for the patients that exceed those derived from Artemether Lumefantrine in tablet dosage form.

The official unveiling of the product, was well-attended by medical experts, held at the MRC Hall of the Lagos State University Teaching Hospital (LASUTH).

Dignitaries at the launch included: Managing Director, Elbe Pharma Nigeria Ltd, Sir Uchenna Obiakor; Pharmanews Publisher, Sir Ifeanyi Atueyi; GM/COO, Elbe Pharma, Shiva Kumar; Prof. O.O Adedeji; Dr Omoniyi Kayode Yemitan of the Department of Pharmacology, Therapeutic and Toxicology LASUTH; Dr W.B Mutiu;  Lagos State Commissioner for Health, Dr Jide Idris;  and representatives of the Pharmaceutical Society of Nigeria(PSN), Association of Community Pharmacists of Nigeria (ACPN) and  National Association of Patent and Proprietary Medicines (NAPPMED).

From L-R Pharm Shiva Kumar GM/COO Elbe pharma, Sir Ifeanyi Atueyi Pharmanews publisher, Prof.O. O Adedeji Dean of Basic Medical sciences LASUTH, Sir Uchenna Obiakor MD Elbe Pharma, Mrs Wale Puloyi Director of drug quality control Laboratory, representing Commissioner of health during the Seminar on preventing treatment failure in Artemether-Lumefantrine & Ground round presentation on Efficacy of new Amatem Softgel Antimalaria: Studies on Bioavailability, Safety and Toxicity held at MRC Hall, LASUTH, Ikeja, Lagos, Nigeria

Speaking on the findings of a comparative study conducted on the bioavailability, efficacy and toxicity of Amatem Forte Softgel and another known brand of Artemeter–Lumefantrine tablet formulation by a group of researchers from LASUTH, Dr Omoniyi Yemitan noted that Amatem Softgel was found to be more bioavailable in the bloodstream than other brands of malaria tablets.

According to him: “It is expected that most of the drugs we take get to the bloodstream; that is what we call bioavailability. What we found out from the bioavailability study is that Amatem Softgel is more present in the bloodstream than the tablets. The implication is that Amatem Softgel can quickly attack malaria parasite in the bloodstream, than tablets.”

He further revealed that the toxicity study of Amatem Softgel did not reveal any major side effects of the drug on patients.

“The study was focused on how much of the product was found in the bloodstream and its effectiveness in treating malaria, and these showed significant positive results,” he said.

Managing Director of Elbe, Sir Uchenna Obiakor, stated that the impressive acceptance that the new product was gaining in the Nigerian market was a testament to its efficacy.

“People have started testifying about the efficacy of the product; in fact, product acceptance for a newly introduced brand is highly encouraging,” he said.

On the affordability of the product to the Nigerian populace, Obiakor noted that the company had deliberately made it easy for people to purchase the product, not minding the quality formulation used in producing it.

“Yes we have done tremendous work on this to ensure that the masses can easily afford the product,” he said. “The novel drug therapy is quite different from that of the tablet, and going by this, it is easily affordable, compared to the therapeutic benefits derived from the formulation.”

The General Manager/Chief Operating Officer, Elbe Pharma, Shiva Kumar, emphasized the import of having such a product as Amatem Forte Softgel that helps in reducing the resistance and associated treatment failures within Nigeria.

Amatem Softgel Launch
The Amatem Softgel Team at the Launch Event

In his contribution, the Brand Manager, Elbe Pharma, Mr. Augustine Aisabokhale, described Amatem Softgel as being far more affordable, “though it is more capital intensive to produce, regarding the technology behind the production.”

Leave a Reply

Your email address will not be published. Required fields are marked *